Limits...
A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Fioravanti M, Nakashima T, Xu J, Garg A - BMJ Open (2014)

Bottom Line: Incidence of any adverse events (AEs) was slightly higher (RR=1.05; 95% CI 0.93 to 1.2) while incidence of serious AEs was lower (RR=0.85; 95% CI 0.50 to 1.45) in the nicergoline compared with placebo group.Frequency of anxiety was significantly lower in nicergoline as compared with placebo (p=0.01).Other AEs including diarrhoea, gastric upset, dizziness and drowsiness were less frequent in the nicergoline group when compared with placebo/active drugs, but the difference was non-significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.

Show MeSH

Related in: MedlinePlus

Results of meta-analysis, all withdrawals: nicergoline versus placebo.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120366&req=5

BMJOPEN2014005090F2: Results of meta-analysis, all withdrawals: nicergoline versus placebo.

Mentions: Total withdrawals with nicergoline ranged from 0%2225 to 22.2%11 and from 0% to 27.8% with other comparator drugs/placebo. Six studies reported a lower number of patient withdrawals from the nicergoline group as compared with other comparator/placebo groups. Withdrawals due to AE were similar in the nicergoline group as compared with other groups across the studies (figure 2).


A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Fioravanti M, Nakashima T, Xu J, Garg A - BMJ Open (2014)

Results of meta-analysis, all withdrawals: nicergoline versus placebo.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120366&req=5

BMJOPEN2014005090F2: Results of meta-analysis, all withdrawals: nicergoline versus placebo.
Mentions: Total withdrawals with nicergoline ranged from 0%2225 to 22.2%11 and from 0% to 27.8% with other comparator drugs/placebo. Six studies reported a lower number of patient withdrawals from the nicergoline group as compared with other comparator/placebo groups. Withdrawals due to AE were similar in the nicergoline group as compared with other groups across the studies (figure 2).

Bottom Line: Incidence of any adverse events (AEs) was slightly higher (RR=1.05; 95% CI 0.93 to 1.2) while incidence of serious AEs was lower (RR=0.85; 95% CI 0.50 to 1.45) in the nicergoline compared with placebo group.Frequency of anxiety was significantly lower in nicergoline as compared with placebo (p=0.01).Other AEs including diarrhoea, gastric upset, dizziness and drowsiness were less frequent in the nicergoline group when compared with placebo/active drugs, but the difference was non-significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.

Show MeSH
Related in: MedlinePlus